How many drugs treat Systemic mast cell disease?

Drug Landscape tracks 9 marketed treatments for Systemic mast cell disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/systemic-mast-cell-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Systemic mast cell disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systemic mast cell disease (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Systemic mast cell disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ayvakit	AVAPRITINIB	Blueprint Medicines	Kinase Inhibitor [EPC]	Platelet-derived growth factor receptor alpha	2020-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Aciphex	rabeprazole	Waylis	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Intal	cromoglicic acid	Pfizer	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01
Aciphex	Aciphex	University of Utah		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X
Cromoglycate	Cromoglycate	Vishwajit Nimgaonkar, MD PhD		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
Cromoglicate	Cromoglicate	LEO Pharma		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
Rabeprazol	Rabeprazol	Janssen-Cilag, S.A.		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Systemic mast cell disease
Blueprint Medicines · 1 drug in Systemic mast cell disease
Janssen-Cilag, S.A. · 1 drug in Systemic mast cell disease
LEO Pharma · 1 drug in Systemic mast cell disease
M.D. Anderson Cancer Center · 1 drug in Systemic mast cell disease
Novartis · 1 drug in Systemic mast cell disease
Pfizer · 1 drug in Systemic mast cell disease
University of Utah · 1 drug in Systemic mast cell disease
Vishwajit Nimgaonkar, MD PhD · 1 drug in Systemic mast cell disease
Waylis · 1 drug in Systemic mast cell disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Systemic mast cell disease:

Cite this brief

Drug Landscape (2026). Systemic mast cell disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/systemic-mast-cell-disease. Accessed 2026-06-10.

Systemic mast cell disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing